BioSpace

Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Not a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reported data bolstering its case to bring to market the first CAR T for an autoimmune disease.

By BioSpace

1 min read
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights